vs
Side-by-side financial comparison of CollPlant Biotechnologies Ltd (CLGN) and Maase Inc. (MAAS). Click either name above to swap in a different company.
CollPlant Biotechnologies Ltd is the larger business by last-quarter revenue ($10.2M vs $9.9M, roughly 1.0× Maase Inc.).
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
CLGN vs MAAS — Head-to-Head
Income Statement — Q2 FY2023 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $9.9M |
| Net Profit | $5.8M | — |
| Gross Margin | 94.0% | 78.7% |
| Operating Margin | 55.7% | -55.9% |
| Net Margin | 56.6% | — |
| Revenue YoY | 15330.3% | — |
| Net Profit YoY | 234.5% | — |
| EPS (diluted) | $0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.3M | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $36.0M | $31.6M |
| Total Assets | $41.6M | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 23 | $22.3M | — | ||
| Q4 22 | — | $10.9M |
| Q2 23 | $36.0M | — | ||
| Q4 22 | — | $31.6M |
| Q2 23 | $41.6M | — | ||
| Q4 22 | — | $47.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-18.2M |
| Free Cash FlowOCF − Capex | — | $-18.3M |
| FCF MarginFCF / Revenue | — | -184.4% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 23 | — | — | ||
| Q4 22 | — | $-18.2M |
| Q2 23 | — | — | ||
| Q4 22 | — | $-18.3M |
| Q2 23 | — | — | ||
| Q4 22 | — | -184.4% |
| Q2 23 | — | — | ||
| Q4 22 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLGN
Segment breakdown not available.
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
